The MDM2-A splice variant of MDM2 alters transformation in vitro and the tumor spectrum in both Arf- and p53-null models of tumorigenesis

Molecular Cancer Research

Volumn 7, Issue 6, 2009, Pages 863-869

  Volk, Erin L ^a   Fan, Liying ^a   Schuster, Katja ^a   Rehg, Jerold E ^a   Harris, Linda C ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; ETHYLNITROSOUREA; PROTEIN MDM2; PROTEIN MDM2 A; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; LATENT PERIOD; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN VARIANT; WILD TYPE;

ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE MODELS, ANIMAL; ETHYLNITROSOUREA; FEMALE; FIBROBLASTS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, GERM CELL AND EMBRYONAL; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

MURINAE; MUS; MUS MUSCULUS;

EID: 67649610426     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0418     Document Type: Article

References (29)

1. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991;10:1565-1569 (Pubitemid 21905621)
2. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53- mediated transactivation. Cell 1992;69:1237-1245
3. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-83
4. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993;53:16-18 (Pubitemid 23019370)
5. Corvi R, Savelyeva L, Breit S, et al. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. Oncogene 1995;10:1081-1086
6. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993;53:2736-2739 (Pubitemid 23180507)
7. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 1996;2:912-917 (Pubitemid 26296763)
8. Bartel F, Taubert H, Harris LC. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2002;2:9-15. (Pubitemid 41043984)
9. Bartel F, Pinkert CA, Fiedler W, Wurl P, Schmidt H, Taubert H. Expression of alternatively and aberrantly spliced transcripts of the MDM2 mRNA is not tumor-specific. Int J Cancer 2004;24:143-151
10. Matsumoto R, Tada M, Nozaki M, Zhang CL, Sawamura Y, Abe H. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res 1998;58:609-613 (Pubitemid 28099465)
11. Lukas J, Gao D-Q, Keshmeshian M, et al. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 2001;61:3212-3219 (Pubitemid 32691978)
12. Dias CS, Liu Y, Yau A, Westrick L, Evans SC. Regulation of hdm2 by stress-induced hdm2alt1 in tumor and nontumorigenic cell lines correlating with p53 stability. Cancer Res 2006;66:9467-9473 (Pubitemid 44623644)
13. Chandler DS, Singh RK, Caldwell LC, Bitler JL, Lozano G. Genotoxic stress induces coordinately regulated alternative splicing of the modulators MDM2 and MDM4. Cancer Res 2006;66:9502-9508 (Pubitemid 44623648)
14. Lents NH, Wheeler LW, Baldassare JJ, Dynlacht BD. Identification and characterization of a novel Mdm2 splice variant acutely induced by the chemotherapeutic agents adriamycin and actinomycin D. Cell Cycle 2008;7:1580-1586 (Pubitemid 351881325)
15. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, Lozano G. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 2001;20:4041-4049 (Pubitemid 32681609)
16. Dang J, Kuo M-L, Eischen C, Stepanova L, Sherr C, Roussel M. The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res 2002;62:1222-1230 (Pubitemid 34160312)
17. Bartel F, Taylor AC, Taubert H, Harris LC. Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines. Oncol Res 2002;12:451-457
18. Fridman JS, Hernando E, Hemann MT, de Stanchina E, Cordon Cardo C, Lowe SW. Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res 2003;63:5703-5706 (Pubitemid 37203378)
19. Volk EL, Schuster K, Nemeth KM, Fan L, Harris LC. MDM2-A, a common Mdm2 splice variant, causes perinatal lethality, reduced longevity and enhanced senescence. Dis Model Mech 2009;2:47-55.
20. Kamijo T, Bodner S, van de Kamp E, Randle DH, Sherr CJ. Tumor spectrum in ARF-deficient mice. Cancer Res 1999;59:2217-2222 (Pubitemid 29217688)
21. de Kok A, Sips H, den Engelse L, Simons J. Transformation of C3H10T1/2 cells by N-ethyl-N-nitrosourea occurs as a single, low frequency, mutation-like event. Carcinogenesis 1986;7:1387-1392
22. Weber J, Salinger A, Justice M. Optimal N-ethyl-N-nitrosourea (ENU) doses for inbred mouse strains. Genesis 2000;26:230-233
23. Selye H, Veilleux R, Cantin M. Excessive stimulation of salivary gland growth by isoproterenol. Science 1961;133:44-45
24. Zeng X, Chen L, Jost CA, et al. MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 1999;19:3257-3266 (Pubitemid 29193787)
25. Zhang Z, Wang H, Li M, Rayburn ER, Agrawal S, Zhang R. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene 2005;24:7238-7247 (Pubitemid 41679285)
26. Sharp DA, Kratowicz SA, Sank MJ, George DL. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem 1999;274:38189-38196 (Pubitemid 30026893)
27. Hogan B, Beddington R, Costnatini F, Lacy E. Manipulating the mouse embryo: a laboratory manual. Cold Spring Harbor Laboratory Press: Plainview; 1994.
28. McKenzie PP, McPake CR, Ashford AA, Vanin EF, Harris LC. MDM2 does not influence p53-mediated sensitivity to DNA-damaging drugs. Mol Cancer Ther 2002;1:1097-1104
29. Sun H, Taneja R. Analysis of transformation and tumorigenicity using mouse embryonic fibroblast cells. Cancer Genomics and Proteomics: Humana Press; 2007. pp. 303-310